Vibegron: First Global Approval.

Article Details

Citation
Copy to clipboard

Keam SJ

Vibegron: First Global Approval.

Drugs. 2018 Nov;78(17):1835-1839. doi: 10.1007/s40265-018-1006-3.

PubMed ID
30411311 [ View in PubMed
]
Abstract

Vibegron is a selective beta 3 adrenergic receptor (beta3AR) agonist that is being developed in Japan jointly by Kyorin Pharmaceutical Co., Ltd and Kissei Pharmaceutical Co., Ltd and in other regions worldwide (except in several other Asian countries) by Urovant Sciences for the treatment of overactive bladder (OAB). Based on results from Japanese phase III trials, vibegron received approval in Japan in September 2018 for this indication. This article summarizes the milestones in the development of vibegron leading to this first global approval for the treatment of OAB.

DrugBank Data that Cites this Article

Drugs